Mandana Kamgar, MD, MPH

Publications

• Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.

  (George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S.) Gastroenterology. 2024 Jan 25 PMID: 38280684 SCOPUS ID: 2-s2.0-85188891214 01/28/2024

• Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review.

  (Mody J, Kamgar M.) Case Rep Oncol. 2024;17(1):399-406 PMID: 38435447 PMCID: PMC10907001 03/04/2024

• Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

  (de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, Christians KK, Clarke CN, George B, Shreenivas A, Kamgar M, Chakrabarti S, Dua KS, Khan AH, Madhavan S, Erickson BA, Hall WA.) Cancer Med. 2023 Dec 22;13(1) PMID: 38140796 PMCID: PMC10807686 SCOPUS ID: 2-s2.0-85180644976 12/23/2023

• Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer.

  (Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S.) Ann Surg. 2023 Dec 01;278(6):e1224-e1231 PMID: 37078282 SCOPUS ID: 2-s2.0-85176508848 04/20/2023

• Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.

  (Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S.) J Surg Oncol. 2023 Jul;128(1):41-50 PMID: 36960919 SCOPUS ID: 2-s2.0-85152449940 03/25/2023

• Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.

  (Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS.) Cancer Causes Control. 2023 May;34(5):459-468 PMID: 36934365 PMCID: PMC10373434 SCOPUS ID: 2-s2.0-85150302312 03/20/2023

• ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

  (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3022 PMID: 36877324 SCOPUS ID: 2-s2.0-85152164746 03/07/2023

• CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.

  (Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S.) Ann Surg Oncol. 2023 May;30(5):3013-3021 PMID: 36788189 SCOPUS ID: 2-s2.0-85147934173 02/15/2023

• Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort

  (Sreeram K, Seaton R, Greenwald MK, Kamgar M, Assad H, Baird T, Schwartz AG, Ruterbusch J, Simon MS.) Cancer Causes and Control. May 2023;34(5):459-468 SCOPUS ID: 2-s2.0-85150302312 05/01/2023

• Comprehensive genomic profiling: Does timing matter?

  (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B.) Front Oncol. 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 03/04/2023

• Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy

  (Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, Hall WA, Azmi AS.) Advances in Radiation Oncology. 1 January 2023;8(1) SCOPUS ID: 2-s2.0-85143485885 01/01/2023